Favipiravir: An Effective Rna Polymerase Modulating Anti-Influenza Drug
Year: 2023
Type: article
Abstract: ABSTRACT: Combination of all the aspects are covered in this review from anti-influenza drug.Several articles neglected to include a point of view. The majority of review papers emphasiseon epidemiology. In order to lessen the financial burden of disease and its negative effects, it is important to raise awareness about disease and how to manage it.The medicine favipiravir,additionally called T-705 (5-fluro-2-oxo-1H-pyrazine-3-carboxamide), by selection and powerfully inhibits the polymer-dependent polymer accelerator (RdRp) of polymer viruses. Favipiravir was discovred by the company Toyama Chemical Co., Ltd.By searching a chemical library for the respiratory illness virus's antiviral properties. Favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), the active version of the drug, is recognised by RdRpas a substrate and restrains the polymer accelerator's activityFavipiravir is efficient against a broad kind of subtypes and variations of respiratory disorder viruses.
DOI: 10.13005/bbra/3102
Authors: Shertate Yash, Kamble Sarika, Borse Laxmikant
Institutions: Sandip Foundation, Savitribai Phule Pune University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4383040653